HPV18-Related Cancer Model Development

Cancers, like cervical cancer and head & neck cancer, are strongly linked to human papillomavirus (HPV) infection. Targeting the HPV virus, particularly through vaccines, is a promising approach for treating HPV-related cancers. Vaccines can be designed to stimulate the immune system to target and eliminate HPV-infected cells, potentially preventing cancer progression or even treating established cancers. Researchers are actively developing novel strategies to target HPV proteins such as E6 and E7, which are key to HPV’s ability to cause cancer.

At AACR 2025, WuXi Biology presented a poster describing the development of two HPV18-related murine syngeneic tumor models that stably express HPV18 E6 and E7 proteins.  The authors used these models to validate the efficacy of an HPV18 self-amplifying RNA (saRNA) LNP vaccine. Results showed that HPV18 saRNA LNP could significantly inhibit tumor growth and activate a T cell immune response, especially HPV18 E6/E7-specific T cells.

AACR 2025 Poster_HPV18 Models

Download